Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer (2)

Publicado 10/12/2018 16:21:10CET

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

References  

1) Blair A B et al. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Current Problems in Cancer (2018)  https://www.sciencedirect.com/science/article/pii/S0147027217301083?via%3DihubAc cessed November 2018 2) Global Burden of Disease Study 2013. The Lancet 2015;385(9963):117-171. 3) Hezel AF et al. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28:3531-40. http://dx.doi.org/10.1200/JCO.2009.27.4787  Accessed November 2018 4) Goldstein D et al. New molecular and immunotherapeutic approaches in biliary cancer. ESMO Open (2017). Published online 2017 Mar 27. doi:  https://dx.doi.org/10.1136%2Fesmoopen-2016-000152 Accessed November 2018 5) Lamarca A, et al. Ann Oncol. 2014;25(12):2328-2338.

Your Contacts Media Relations friederike.segeberg@merckgroup.com Phone: +49-6151-72-6328 Investor Relations investor.relations@merckgroup.com Phone: +49-6151-72-3321

(Logo: https://mma.prnewswire.com/media/765882/Merck_Logo.jpg )

Photo: https://mma.prnewswire.com/media/765882/Merck_Logo.jpg

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación